Clinigen Signs Exclusive Supply & Distribution Agreement with Lukare for Elliotts B® Solution
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Lukare Medical (‘Lukare’) to manage the supply and distribution of Elliotts B® Solution.
Under the terms of this supply and distribution agreement with Lukare, Clinigen will provide physicians and pharmacists with access to Elliotts B® Solution on an unlicensed, on-demand basis for patients around the world, excluding the US and Canada.
Marketing authorisation is granted in the United States, but Elliotts B® Solution is currently unavailable to meet patient needs elsewhere in the world.
Elliotts B® Solution (buffered intrathecal electrolyte/dextrose injection) is a diluent for methotrexate sodium, a chemotherapeutic drug and immune system suppressant, and cytarabine, a chemotherapeutic drug. These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukaemia or lymphocytic lymphoma.
Julie Gosper, Head of Global Access, Clinigen, said: “We look forward to working with Lukare Medical to make Elliotts B® Solution available on an unlicensed basis outside the US and Canada. This partnership demonstrates our ongoing commitment to supply the right medicine to the right patient at the right time, to improve the quality of people’s lives around the world.”
Edwin Hernandez, CEO, Lukare Medical, said: “We are pleased to form this partnership with Clinigen. This relationship will greatly enhance our ability to make Elliotts B® Solution available to other regions of the world. We are confident many patients and researchers will benefit from the opportunity to use Elliotts B® Solution.”
Under the terms of this supply and distribution agreement with Lukare, Clinigen will provide physicians and pharmacists with access to Elliotts B® Solution on an unlicensed, on-demand basis for patients around the world, excluding the US and Canada.
Marketing authorisation is granted in the United States, but Elliotts B® Solution is currently unavailable to meet patient needs elsewhere in the world.
Elliotts B® Solution (buffered intrathecal electrolyte/dextrose injection) is a diluent for methotrexate sodium, a chemotherapeutic drug and immune system suppressant, and cytarabine, a chemotherapeutic drug. These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukaemia or lymphocytic lymphoma.
Julie Gosper, Head of Global Access, Clinigen, said: “We look forward to working with Lukare Medical to make Elliotts B® Solution available on an unlicensed basis outside the US and Canada. This partnership demonstrates our ongoing commitment to supply the right medicine to the right patient at the right time, to improve the quality of people’s lives around the world.”
Edwin Hernandez, CEO, Lukare Medical, said: “We are pleased to form this partnership with Clinigen. This relationship will greatly enhance our ability to make Elliotts B® Solution available to other regions of the world. We are confident many patients and researchers will benefit from the opportunity to use Elliotts B® Solution.”
